title: High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation Group.
abstract: We evaluated thiotepa in escalating dose in a broad phase I and II study using cryopreserved autologous bone marrow transplantation to assure hematopoietic recovery. Thiotepa was administered intravenously (IV) over two hours daily for three consecutive days followed in three to four days by marrow transplantation. The daily dose ranged from 60 to 525 mg/m2 (total dose, 180 to 1,575 mg/m2). A total of 71 patients with malignant melanoma were treated. Forty-three patients (61%) had received prior cytotoxic therapy and 28 were untreated. Sixty-two patients (87%) had melanoma disseminated to at least one visceral site, nine patients had skin and/or lymphatic metastases only. As of January 1, 1988 one patient was too early to be evaluated, 15 patients were inevaluable for tumor response, four patients had a complete response (CR), and 25 patients had a partial response (PR) to treatment. The response rates (95% confidence interval) for the 55 evaluable patients and for all 71 treated patients were 53% (40% to 65%) and 41% (30% to 53%), respectively. The median duration of response was 3 months, with a range of 1 to 31 + months. Three patients were alive and well without evidence of tumor more than 1 year after treatment. Analysis of patient subsets indicated that neither total dose, previous cytotoxic therapy, or sites of metastases influenced response rate. In this study, high-dose thiotepa has demonstrated a high response rate in patients with metastatic malignant melanoma with both PRs and CRs noted. Although most of the responses were not durable, 10% of the responses lasted more than 1 year. Future studies will evaluate additional methods for increasing the response rate and improving the duration of response.
authors.affiliation: Vanderbilt University, Nashville, TN 37232.
authors.forename: S N
authors.initials: SN
authors.lastname: Wolff
authors.forename: R H
authors.initials: RH
authors.lastname: Herzig
authors.forename: J W
authors.initials: JW
authors.lastname: Fay
authors.forename: C F
authors.initials: CF
authors.lastname: LeMaistre
authors.forename: D
authors.initials: D
authors.lastname: Frei-Lahr
authors.forename: J
authors.initials: J
authors.lastname: Lowder
authors.forename: B
authors.initials: B
authors.lastname: Bolwell
authors.forename: L
authors.initials: L
authors.lastname: Giannone
authors.forename: G P
authors.initials: GP
authors.lastname: Herzig
mesh_terms: D000328:Adult; D000368:Aged; D016026:Bone Marrow Transplantation; D001932:Brain Neoplasms / Q000556:secondary / Q000628:therapy; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008545:Melanoma / Q000556:secondary* / Q000628:therapy*; D008875:Middle Aged; D012074:Remission Induction; D013852:Thiotepa / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D013852:Thiotepa